The provider of health information was among the most active names on the Nasdaq Monday.

Lowers cost of initial doctor visits concerning symptoms/diagnosis of ailment(s)

WebMD (WBMD) was upgraded from Hold to Buy at Citigroup. $35 price target. WBMD has a strong outlook of growth acceleration and margin expansion that highlights it for potential M&A activity in the coming future.

??

23.3

23.3

From Barron's 5-7-07

"WBMD reports 1Q07 results ahead of its guidance and expectations; 2H07 outlook stronger than expected; company raises guidance; valuation improving, but still a little rich; raising estimates; initiating 12-month price target of 53; maintain Hold. We continue to recommend that investors gain exposure to the paradigm shift in health-care marketing spending toward the Web and to the adoption of consumer-driven health-care plans through WBMD and its parent, Emdeon Corp (HLTH). However, we continue to believe that current valuation, although now more attractive (the stock has declined about11% over past two to three weeks), reflects the company's near-term growth potential. Our new fair-value estimate for WBMD is 46 and our 12-month price target is 53."

Downgraded by Needham & Co from Hold to Underperform

LT Holding,good story

Upgraded by Citigroup from Sell to Hold